Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201638 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL12201657 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL9684500 | 0.94 | KMT2A (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL8795712 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL28463566 | 0.86 | ANPEP (0.47) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL14018975 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL6846193 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL23781483 | 0.83 | ANPEP (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL20093612 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL15671001 | 0.83 | ANPEP (0.45) | USP2SMN1; SMN2HPGDTP53ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200269187-A1 | ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2020-08-27 | — | — | US | claimed |
| EP-3678756-A1 | ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE | BASF SE (DE) | 2020-07-15 | — | — | EP | claimed |
| CN-111093803-A | Absorbent and process for selective removal of hydrogen sulfide | 巴斯夫欧洲公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019043099-A1 | ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE | BASF SE (DE) | 2019-03-07 | — | — | WO | claimed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11458433-B2 | Absorbent and process for selectively removing hydrogen sulfide | BASF SE (DE) | 2022-10-04 | — | — | US | disclosed |
| WO-2022164997-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | USP2 4219/4885SMN1; SMN2 1055/4885HPGD 1466/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | USP2 4227/4885SMN1; SMN2 1321/4885HPGD 317/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | USP2 122/4885SMN1; SMN2 1811/4885HPGD 3623/4885 |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | USP2 2073/4885SMN1; SMN2 4077/4885HPGD 539/4885 |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | KCNH2, KCNJ2, KCNQ1 | USP2 3691/4885SMN1; SMN2 4502/4885HPGD 2662/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | USP2 3356/4885SMN1; SMN2 1649/4885HPGD 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.